Clinician and Patient Resources

Clinician Resources

Treatment Guidelines

Mikhael J, et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019;37:1228-63.

Moreau P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52-61.

NCCN Clinical Practice Guidelines: Multiple Myeloma

Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-46.

Current and Emerging Treatment Landscape

Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms National Cancer Institute

Chim CS, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia.2018;32:252-62.

Nijhof IS, et al. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs.2018;78:19-37.

Swan D, et al. Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. Ther Adv Hematol.2019;10:2040620719854171.

Selected Pivotal Trials (listed by publication date)

MM-003: Miguel JS, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol.2013;14:1055-66.

PANORAMA-1: San-Miguel JF, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195-206.

Ixazomib/lenalidomide/dexamethasone: Kumar SK, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol.2014;15:1503-12.

ASPIRE: Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med.2015;372:142-52.

ELOQUENT-2: Lonial S, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med.2015;373:621-31.

ENDEAVOR: Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol.2016;17:27-38.

Sirius: Lonial S, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet.2016;387:1551-60.

Tourmaline-MM1: Moreau P, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med.2016;374:1621-34.

CASTOR: Palumbo A, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375:754-66.

POLLUX: Dimopoulos MA, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375;1319-31.

MMY1001: Chari A, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood.2017;130:974-81.

ARROW: Moreau P, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953-64.

ELOELOQUENT-3: Dimopoulos MA, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018;379:1811-22.

OPTIMISMM: Richardson PG, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781-94.

Shared Decision Making

Strategy 6I: Shared Decision Making Agency for Healthcare Research and Quality

SHARE Fact Sheet Agency for Healthcare Research and Quality

Shared Decision Making National Resource Center Mayo Clinic

Shared decision making in oncology: A model based on patients’, health care professionals’, and researchers’ views. Bomhof-Roordink H, et al. Psychooncology. 2019;28:139-146.

Clinical Trials

Registered Clinical Trials That Are Interventional Studied With Estimated Primary Completion Dates Within the Next 24 Months

Registered Clinical Trials That are Recruiting or Enrolling by Invitation

Treatment Clinical Trials for Multiple Myeloma National Cancer Institute

Patient Resources

Shared Decision Making

I Wish I Had Asked That! Informed Medical Decisions Foundation

Preparing For a Health Care Visit The Empowered Patient Coalition

Ottawa Personal Decision Guide

Managing Side Effects

Symptoms, Side Effects, and Complications Multiple Myeloma Research Foundation

Treatment and Side Effects Management of Multiple Myeloma Cancer Support Community

Managing Symptoms and Treatment Side Effects of Multiple Myeloma CancerCare

Coping with Multiple Myeloma Oncology Nurse Advisor

How to Manage the Side Effects of Multiple Myeloma Treatment WebMD

Multiple Myeloma: Coping with Treatment Cancer.Net - Doctor-Approved Patient Information from ASCO

General Multiple Myeloma Information

Multiple Myeloma Cancer.Net - Doctor-Approved Patient Information from ASCO

Multiple Myeloma Patient Handbook International Myeloma Foundation

Myeloma: For Patients and Survivors Cancer Care

Clinical Trials

Myeloma Matrix 2.0 International Myeloma Foundation

SparkCures: Multiple Myeloma

Multiple Myeloma Organizations

International Myeloma Foundation (IMF)

Myeloma Beacon

Multiple Myeloma Research Foundation (MMRF)